| ACR Image Metrix Formalizes Imaging Biomarker Development Program |
|
|
|
![]() |
![]() |
| Tuesday, 18 October 2011 16:27 | |||
|
ACR Image Metrix™, a global imaging contract research organization (CRO) with expertise in imaging trial design, techniques and data extraction, has formalized a biomarker and imaging development program.
ACR Image Metrix has partnered with radiopharmacies to overcome the challenging logistics of using radiolabeled tracers as biomarkers in clinical research and has formalized a biomarker imaging development program that includes clinical strategy, trial design and execution. “ACR Image Metrix has extensive experience and understands the challenges with biomarkers,” stated Michael J. Morales, general manager. “Our strong operational expertise and infrastructure ensure our clients’ data meet regulatory requirements. Additionally, we are currently assisting several sponsors with their biomarker clinical development programs in multiple therapeutic categories. This is a new area for sponsors as well as the FDA, and ACR Image Metrix is adding incredible value to this new frontier in drug development. “Imaging is being used in earlier research phases as a biomarker to help clarify mechanisms, demonstrate drug activity and provide clinical data to determine whether a device might prove worthwhile,” Morales added. “This approach saves time and money because, if used properly, imaging can lower the variability in influencing go/no-go decisions.” As a leading imaging CRO, ACR Image Metrix specializes in providing imaging CRO services to assist pharmaceutical, biotech and medical device companies around the world. About ACR Image Metrix™ Source:biowire
|
| Add comment | Add to my library | Forward this article |